# Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

> **NCT02402920** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 83 (actual)

## Conditions studied

- Extensive Stage Small Cell Lung Carcinoma
- Limited Stage Small Cell Lung Carcinoma
- Neuroendocrine Neoplasm

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Etoposide
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Radiation Therapy

## Key facts

- **NCT ID:** NCT02402920
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-22
- **Primary completion:** 2025-12-23
- **Final completion:** 2026-02-09
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02402920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02402920, "Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02402920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*